PNC Financial Services Group
MPLT icon

PNC Financial Services Group’s MapLight Therapeutics MPLT Stock Holding History

PNC Financial Services Group’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.22K Buy
316
+222
+236% +$4.17K ﹤0.01% 4677
2026
Q2 		$3.37K Buy
+94
New +$2.7K ﹤0.01% 4529

Other funds holding MPLT

Nan Fung Group Holdings
Nan Fung Group Holdings Kai Tak, Hong Kong $150M AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

PNC Financial Services Group's MPLT Position: Q3 2026 in Review

PNC Financial Services Group increased its MapLight Therapeutics (MPLT) stake by 236% in Q3 2026, buying an estimated $4.17K and bringing the position to 316 shares worth $3.22K. The position accounts for ﹤0.01% of the portfolio, ranked #4677.

PNC Financial Services Group first reported a position in MPLT in Q2 2026 and has held it in 2 quarters since. The position peaked at $3.37K in Q2 2026. 60 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.

  • PNC Financial Services Group held 316 shares of MapLight Therapeutics worth $3.22K as of Q3 2026.
  • PNC Financial Services Group bought 222 MapLight Therapeutics shares in Q3 2026, an estimated $4.17K.
  • MapLight Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4677 holding.
  • PNC Financial Services Group first reported a position in MapLight Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • PNC Financial Services Group's MapLight Therapeutics position peaked at $3.37K in Q2 2026.
  • 60 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.